|
Reuters Health Information: AbbVie gets FDA approval for Hep C combination therapy
AbbVie gets FDA approval for Hep C combination therapy
Last Updated: 2015-07-24
By Reuters Staff
(Reuters) - The U.S. Food and Drug Administration approved
AbbVie Inc's treatment that targets hepatitis C virus with the
rarest genotype.
The treatment called Technivie combines ombitasvir,
paritaprevir and ritonavir and is for use in combination with
ribavirin for patients with HCV genotype 4 infections without
scarring and poor liver function (cirrhosis), the regulator said
on Friday.
The FDA said the combination therapy was the first to show
safety and efficacy in treating HCV genotype 4 infections
without interferon.
About 2.7 million Americans are infected with HCV, of which
genotype 4 is among the least common, according to the Centers
for Disease Control and Prevention.
The three drugs included in Technivie are also in Viekira
Pak, AbbVie's treatment for HCV genotype 1 infection.
"Today's approval provides the first treatment option for
patients with genotype 4 HCV infections without requiring use of
interferon," Dr. Edward Cox of the FDA said in a statement.
|
Stay Informed!
